Incannex (ASX:IHL) share price up on patent application announcement

Shares in the medicinal cannabis pharmaceutical company were released from a trading halt today.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Incannex Healthcare Ltd (ASX: IHL) share price stormed 5.45% higher to 29.5 cents after resuming trade this morning.

In early afternoon, the share price has retreated to 28 cents, up 1.82% on its previous closing price.

Shares in the medicinal cannabinoid pharmaceutical company were placed in a trading halt earlier this week.

The shares began trading again this morning after a positive company announcement.

Let's take a look at the details.

Patent application for sleep apnoea treatment

Incannex announced that it has filed an International Patent Application for its IHL-42X development program.

The patent application refers to its IHL-42X formulation in the treatment of obstructive sleep apnoea.

The application includes key markets such as the US, European Union, Japan and Australia.

The company included interim data from its phase 2b clinical trial in the application.

Incannex receives ethics approval for studies

Incannex also announced that it has received ethics approval for its IHL-42X open label extension study.

The study will allow the company to recruit people who have experienced a benefit from IHL-42X in the phase 2b trial.

 CEO and Managing Director of Incannex Healthcare, Joel Latham noted:

"We are delighted to have received ethics approval to proceed with our open label extension study. Patients who have finished their dosing regimens in the phase 2b trial are now eligible to use IHL-42X every day for an extended period and the data we gather from this program will be invaluable to our ongoing FDA development plan".

More on the Incannex share price

Incannex is a clinical-stage pharmaceutical development company that develops medicinal cannabis pharmaceutical products and psychedelic medicine therapies.

Incannex has a pipeline of patents including IHL-216A, which targets traumatic brain injury and IHL-42X for sleep apnoea.

The Incannex share price has soared by more than 83% since the start of the year. On a 52-week basis, the Incannex share price has risen by almost 300%.

Incannex has a market capitalisation of just over $293 million.

Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Two excited woman pointing out a bargain opportunity on a laptop.
Opinions

2 great value ASX shares I want to buy

These stocks are high on my watchlist.

Read more »

Broker looking at the share price.
Share Market News

5 things to watch on the ASX 200 on Tuesday

Here's what to expect on the local market today.

Read more »

A young woman sits with her hand to her chin staring off to the side thinking about her investments.
Broker Notes

Down 16% in 6 weeks: Is this ASX 200 share a bargain buy?

Bell Potter has given its verdict on this beaten down stock.

Read more »

Ten smiling business people wave to the camera after receiving some winning company news.
Share Gainers

Here are the top 10 ASX 200 shares today

The ASX 200 enjoyed a strong start to the trading week today.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these shares.

Read more »

A young woman sits at her desk in deep contemplation with her hand to her chin while seriously considering information she is reading on her laptop
Opinions

1 ASX 200 dividend stock down 20% to buy right now

This beaten-up ASX share could be a top pick for dividends and stability.

Read more »

Man sitting in a plane looking through a window and working on a laptop.
Opinions

2 cheap ASX 200 shares I'd buy in May

I think these stocks are too cheap to ignore.

Read more »

Smiling couple looking at a phone at a bargain opportunity.
Share Gainers

Why Gentrack, New Hope, Nuix, and Star Entertainment shares are charging higher

These shares are starting the week strongly. But why?

Read more »